The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Cladribine-based chemotherapy for patients with secondary AML arising after MPNs
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of cladribine-based chemotherapy in patients with secondary acute myeloid leukemia (AML) arising from myeloproliferative neoplasms (MPNs). Dr Masarova notes that this is a promising, effective approach in this patient population, and most notably, 40% of patients without stem cell transplantation (SCT) were alive 12 months following therapy initiation. Somewhat unsurprisingly, salvage patients who were pre-treated with hypomethylating agents (HMAs) had lower response rates and poorer survival outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Board of Directors/Advisory Committee: MorphoSys US
